We are thrilled to see Autolomous CEO, Alexander Seyf, contribute to the newest edition of the Cell & Gene Therapy Review. Their quarterly publication offers objective insights into the industry’s most critical sectors spanning the entire lifecycle of therapeutics, from initial R&D and gene editing to manufacturing, analytical controls, and regulatory navigation.

Alexander contributes to their 2026 predictions feature, offering his thoughts on the direction of the Cell and Gene Therapy industry.

Some key insights from his excerpt include:
→ Maturing Industry Focus: The sector is shifting from “hype” toward scalable, grounded success by prioritising solutions for core pain points like delivery, cost, and reliability.
→ Diversifying R&D: Research is expanding beyond oncology, with over 51% of new gene therapy trials targeting non-oncology indications through digitally flexible, multi-indication platforms.
→ Manufacturing Transformation: To combat high batch costs, companies are replacing legacy systems with intelligent, closed-system automation and GMP-compliant software to ensure data integrity and real-time visibility.

Download Cell and Gene Therapy’s latest release here to read more!